OBJECTIVE It is well known that bromocriptine has a suppressive effect on the prolactin release in hyperprolactinemic patients. But it also has some adverse effects. The new, long-acting dopaminergic drug, cabergoline, has been reported to be an effective agent in these patients. However, there are relatively few reports comparing the beneficial and adverse effects of these drugs in the treatme...

BACKGROUND Cabergoline is a long-acting dopamine-agonist drug that suppresses prolactin secretion and restores gonadal function in women with hyperprolactinemic amenorrhea. We designed a study to compare its safety and efficacy with those of bromocriptine, which has been the standard therapy. METHODS A total of 459 women with hyperprolactinemic amenorrhea were treated with either cabergoline ...

Pleurisy of initially unknown origin was found in a patient who was treated with bromocriptine for Parkinson's disease for 6 years. At presentation, bilateral pleural thickening existed that caused severe restriction of pulmonary function. There were an elevated erythrocyte sedimentation rate, polyclonal hypergammaglobulinaemia, increased levels of acute phase proteins and anaemia. After withdr...

This study was designed to demonstrate that dopaminergic stimulation would result in decreased smoking behavior and nicotine intake, whereas dopaminergic blockade would result in increased smoking behavior and nicotine intake, in the same subjects. In prior human studies, a dopaminergic antagonist, haloperidol, increased smoking and/or nicotine intake, and a dopamine agonist, bromocriptine, dec...

Bromocriptine (2-bromo-a-ergocryptine) inhibited prolactin release when added to primary cultures of dispersed pituitary glands from male rats. The total amount of prolactin (intracellular plus extracellular) was reduced to less than 20% of control values after 6 days. The amount of intracellular prolactin was increased in treated cultures and the total amount of hormone was the same in control...

The metabolic syndrome comprises a cluster of metabolic anomalies including insulin resistance, abdominal obesity, dyslipidemia, and hypertension. Previous studies suggest that impaired dopamine D2 receptor (D2R) signaling is involved in its pathogenesis. We studied the acute effects of bromocriptine (a D2R agonist) on energy metabolism in obese women; body weight and caloric intake remained co...

abstract injection of sulpiride (d2 receptor antagonist, antipsychotic drug) into vmn hypothalamus, increased gastric volume secretion and decreased gastric ph. the present study the effect of sch23390 (d1 dopamine receptor antagonist) on the gastric acid secretion and its acidity were studied. 70 rats were divided into 7 groups: two control groups, two sham groups given medicine solvents, a sc...

Introduction: The protective and antisecretory effects of dopamine agonists on the stomach have been already reported, but the effect of bromocriptine (D2 dopamine agonist) on histamine stimulated gastric acid secretion (GAS) needs to be investigated. Methods: For gastric sampling, animals were anesthetized and a polyethylen tube was introduced into the stomach through esophagus. A cannula ...

Sixty-three patients with Parkinson's disease who failed bromocriptine therapy for various reasons were treated in an open-label trial of pergolide. The data were evaluated in a retrospective manner. Forty-six percent had a good response and tolerated the pergolide. A comparison of the outcomes regarding response and toxicity revealed that bromocriptine and pergolide act differently in individu...

Prolactin-secreting pituitary tumors are now recognized as a common endocrinologic problem [1]. Bromocriptine is an ergot alkaloid which, by virtue of its agonist action at the dopamine receptor, is effective in lowering serum prolactin levels [2). Although a number of reports have shown reduction in tumor size with bromocriptine therapy [3-8], documentation of rapid regression of tumor size is...